PET Groups Carp On CMS Coverage Policy, National Coverage Decision Delay
This article was originally published in The Gray Sheet
Executive Summary
CMS' cautious approach to covering positron emission tomography indications has spurred criticism among the PET industry, which seeks to accelerate reimbursement to drive the technology's adoption
You may also be interested in...
MIC Banks On PET/CT Services To Offset Siemens, GE Device Leasing Costs
Molecular Imaging Corp. plans to refocus its business strategy on providing integrated PET/CT imaging services to its hospital, physician group and diagnostic imaging center customers, rather than concentrating on PET services alone
MIC Banks On PET/CT Services To Offset Siemens, GE Device Leasing Costs
Molecular Imaging Corp. plans to refocus its business strategy on providing integrated PET/CT imaging services to its hospital, physician group and diagnostic imaging center customers, rather than concentrating on PET services alone
CMS To Help Build National FDG-PET Cancer Registry, Will Cover Trials
CMS plans to work with stakeholders to develop a national registry as well as small studies to determine the clinical utility of FDG-PET in the management of brain, ovarian, pancreatic and small-cell lung cancers